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Abstract
Background: The activity of the ribonucleoprotein enzyme telomerase is detectable in germ,
stem and tumor cells. One major component of telomerase is human telomerase reverse
transcriptase (hTERT), which encodes the catalytic subunit of telomerase. Here we investigate the
correlation of telomerase activity and hTERT gene expression and the differentiation status of
primary testicular germ cell tumors (TGCT).
Methods: Telomerase activity (TA) was detected by a quantitative telomerase PCR ELISA, and
hTERT mRNA expression was quantified by online RT-PCR in 42 primary testicular germ cell
tumors. The control group consisted of benign testicular biopsies from infertile patients.
Results: High levels of telomerase activity and hTERT expression were detected in all examined
undifferentiated TGCTs and in the benign testicular tissue specimens with germ cell content. In
contrast, differentiated teratomas and testicular control tissue without germ cells (Sertoli-cell-only
syndrome) showed no telomerase activity and only minimal hTERT expression.
Conclusions: These findings demonstrate an inverse relationship between the level of telomerase
activity and hTERT mRNA expression and the differentiation state of germ cell tumors.
Quantification of telomerase activity and hTERT mRNA expression enables a new molecular-
diagnostic subclassification of germ cell tumors that describes their proliferation potential and
differentiation status.
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Background
Testicular germ cell tumors (TGCT) are the most frequent
malignant disease in young men [1].
The current parameters for treatment stratification enable
stage-related therapy only to a limited degree [2]. This
study evaluates the suitability of telomerase activity and
the gene encoding the catalytic subunit of telomerase (hu-
man telomerase reverse transcriptase, hTERT) as a poten-
tial diagnostic marker for evaluating the differentiation
status of testicular germ cell tumors.
Telomerase functions as an intracellular reverse tran-
scriptase that catalyzes the synthesis and extension of tel-
omeres [3]. Telomeres, the distal ends of linear eukaryotic
chromosomes, are composed of hexanucleotide repeats
(TTAGGG)n. They protect the encoding DNA sequences
from damage and destabilization by binding various pro-
teins. Most human somatic cells lose telomeric repeat se-
quences with each cell division, which leads to replicative
senescence [4,5]. In contrast, germline, stem, and most tu-
mor cells are believed to be immortal because telomere
length is maintained by the enzyme telomerase [6]. One
major component of the active enzyme is the catalytic
subunit human telomerase reverse transcriptase (hTERT)
[7–10]. hTERT mRNA is expressed almost exclusively in
malignant tumors as well as in stem and germ cells and
correlates closely with the detection of telomerase activity
[7–10]. Ectopic hTERT expression in combination with
two oncogenes (SV40 large-T and H-ras) has been shown
to cause tumorigenic conversion of normal human epi-
thelial and fibroblast cells in experimental settings [11].
Thus the telomerase catalytic subunit appears to play a
central role in human carcinogenesis.
Telomerase detection was used to differentiate between
benign and malignant tissue in a large number of tumors
[6]. Telomerase activity [12–16] and hTERT mRNA [16–
18] were identified as potential prognostic markers in
some tumor entities.
Though telomerase detection correlates with malignancy
in the majority of cancers, this is not the case in testicular
germ cell tumors, since germ cells possess high intrinsic
telomerase activity[19]. The latter might actually provide
the basis for the development of testicular germ cell tu-
mors, which are histogenetically derived from germline
cells [20,21]. Here, an important prerequisite for the
growth of cancer cells, i.e. immortalization by reactivation
of telomerase, already exists and thus accelerates carcino-
genesis.
The presence or absence of telomerase activity appears to
be unrelated to telomere length in testicular germ cell tu-
mors [22]. In addition, an inverse correlation was found
between telomerase activity and tumor differentiation
[23]. Moreover, an association has been reported between
increasing tumor differentiation and downregulation of
human telomerase RNA expression [24].
We previously corroborated these findings in a limited set
of human GCT specimens and human testicular tumor
cell lines by demonstrating that telomerase activity is high
in seminomas and nonseminomas but low in differentiat-
ed teratomas and cells submitted to cisplatin treatment
[25].
In this study, histologic findings in primary adult human
testicular germ cell tumors were correlated with levels of
telomerase activity and hTERT mRNA expression, which
were quantified by a quantitative PCR ELISA and real-time
fluorescence RT PCR respectively.
Methods
Patients and sample collection
Primary testicular germ cell tumors were obtained from
42 patients at the time of primary orchiectomy. The exam-
ination was done in tissue samples with predominant
components (>80 %) of the individual tumor entities
(e.g., embryonal carcinoma, immature teratoma, etc.). In
7 of the 42 cases, samples were also examined from adja-
cent intratubular germ cell neoplasia of the unclassified
type (ITGCNU) (synonym: carcinoma in situ, CIS, testic-
ular intraepithelial neoplasia [26] with a tubular compo-
nent >30%. The control group comprised testicular tissue
samples from 38 patients with infertility. All specimens
were collected from 1997 to 2000 at the Departments of
Anatomy and Andrology, the University Hospital Ham-
burg Eppendorf and at the Department of Urology, the
University Hospital Benjamin Franklin, Berlin. The use of
the tissue specimens was approved by the Institutional Re-
view Boards.
Histological workup
Tissue samples were divided after removal. One part was
snap-frozen, and the other part was histologically ana-
lyzed. This procedure enabled direct correlation of the his-
topathological and molecular parameters. All snap-frozen
tissue specimens were serially sectioned. The first and last
five sections were cut into 5 µm slices and stained with he-
matoxylin-eosin to assess tissue preservation and check
the histopathological classification.
This procedure ensured the examination of tissue samples
with predominant components of the respective tumors
(>80%).
The formalin-fixed and paraffin-embedded tumors were
assessed according to the WHO classification [27]. Hema-
toxylin-eosin staining was supplemented by immunohis-BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/32
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tochemistry, including placental alkaline phosphatase
(PLAP) and CD31/factor-VIII as well as monoclonal anti-
gen Ki-67 for some tissue specimens and cytokeratin-20
for seminomas.
Biopsy material of the control group was fixed in Stieve
solution, stained with hematoxylin-eosin and PLAP and
histologically evaluated according to a modified Johnsen
Score [28].
RNA extraction
Tissue for RNA and protein extraction was obtained from
15 µm intermediate sections. Total RNA was extracted us-
ing the RNAzolB™ extraction kit (WAK-Chemie Medical,
Bad Homburg, Germany) according to the manufacturer's
instructions, and its quality was assessed as previously de-
scribed [25]. In brief, the RNA yield was quantified by UV
spectrophotometry, and one microgram of total RNA was
subjected to 1% agarose gel electrophoresis. Preservation
of 28S and 18S rRNA species was used to assess RNA in-
tegrity. Samples without detection of 28S/18S RNA were
excluded from further examination.
Protein extraction
As already described previously [29], the tissue specimens
obtained by orchiectomy were prepared for the detection
of telomerase activity as follows.
First the tissue samples were lysed using 200 µl of lysis
buffer (10 mM tris-HCl [pH7.5], 1 mM MgCl2, 1 mM EG-
TA, 0.1 mM phenylmethylsufonyl fluoride, 5 mM β-mer-
captoethanol, 0.5% 3 - [(3 - chloroamino - dopropyl)
dimethylamino] - 1 propanesulfate (CHAPS), 10% glycer-
ol) according to the method of Kim et al. [6]. After 30 min
of incubation on ice, the lysate was centrifuged at 14,000
× g for 30 min at 4°C. The supernatant was aliquoted,
flash-frozen in liquid nitrogen and stored at -80°C. The
protein concentration of the extract was measured by the
biuret method.
Detection of telomerase activity
A quantitative telomerase PCR ELISA kit (TeloTAGGG Te-
lomerase PCR ELISA (PLUS), Roche Molecular Biochemi-
cals, Mannheim, Germany) was used according to the
manufacturer's instructions to detect PCR products em-
ploying biotin-labeled TS primer as previously described
[30,31]. The assay is essentially the same as the one de-
scribed by Kim et al. [6], but, instead of radioactive nucle-
otide labeling, biotinylated primers were used during the
extension reaction, thus enabling quantitative photomet-
ric detection by a streptavidin-DIG-peroxidase immuno-
reaction.
Quantitative detection of human telomerase catalytic sub-
unit (hTERT) messenger RNA
Quantitative detection of hTERT mRNA was performed
with the commercially available LightCycler Telo TAGGG
hTERT Quantification Kit® (Rouche Diagnostics GmbH,
Mannheim, Germany) using the LightCycler® instrument
(Roche Molecular Systems, Alameda, CA) for real-time
PCR. All subsequent quantification steps were performed
according to the manufacturer's instructions.
The recently introduced LightCycler®[32] is a thermocy-
cler with on-line monitoring of PCR products. The ampli-
con is detected by fluorescence using two short
oligonucleotides that hybridize to an internal sequence of
the amplified fragment during the annealing phase of the
PCR cycles. One probe is labeled with a fluorescent dye at
the 5' end, the other with fluorescein at the 3' end. The
probes are designed to hybridize to the target strand so
that the two dyes are in close proximity and fluorescence
resonance energy transfer takes place between the two
fluorophores. This leads to the emission of fluorescence,
which is detected on-line during the PCR cycles.
Briefly, hTERT encoding mRNA was reverse-transcribed
(10 min at 60°C), followed by denaturation of the RNA/
DNA complex (30 sec at 95°C) and amplification of a 198
bp fragment of the generated cDNA in 40 PCR cycles (0.5
sec at 95°C; 10 sec at 60°C; 10 sec at 72°C) with specific
primers in a one-step RT-PCR reaction. The following
were prepared for each PCR assay: 2 µl of hTERT reaction
mix, 0.1 µl of reverse transcriptase, 2 µl of hTERT or PBGD
detection mix, 13.9 µl of H20 and 2 µl of standard RNA
template (1–5) / 100 ng/1 µl of total RNA from an hTERT-
positive cell line / H20 or sample RNA.
The same RT-PCR for mRNA encoding the housekeeping
gene for porphobilinogen deaminase (PBGD) was per-
formed in separate tubes. The reaction product served as a
control for RT-PCR and as a reference for relative quanti-
fication of hTERT mRNA and hTR.
To provide a positive control and establish an external
standard curve, all measurements included the determina-
tion of 5 standards with in-vitro-transcribed hTERT
mRNA containing 1.3 × 106, 9.8 × 104, 8.0 × 103, 7.2 ×
102 and 1.4 × 102 copies/2 µl as well as total RNA purified
from an hTERT mRNA-expressing cell line supplied by the
detection kit. The graph of the linear regression and calcu-
lation of the regression coefficient r served to confirm the
accuracy and reproducibility of this approach. Total RNA
was used as a positive control for detection of PBGD mR-
NA. Probes without template that otherwise fulfilled the
same requirements were examined as negative controls.
Each sample was normalized on the basis of its PBGD
content according to the formula NhTERT = hTERT mRNABMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/32
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copies per sample / (PBGD mRNA copies per sample /
1000).
Probes were evaluated as hTERT mRNA-positive when the
measurement of standard probes and controls yielded ad-
equate results and > 400 copies of PBGD mRNA were de-
tected, suggesting an appropriate initial quantity and
quality of total RNA. They were assessed as negative when
no hTERT mRNA was detected in the presence of > 400
copies of PBGD mRNA.
Statistical analysis
Statistical analysis was performed using the Kruskal-Wal-
lis test for nonparametric analysis of variance to compare
the histological subgroups. The correlation of NhTERT and
telomerase activity was evaluated by using the Spearman's
test. A discriminant analysis of NhTERT and telomerase ac-
tivity was also performed for the different histological
subgroups. Values were expressed as follows: mean, stand-
ard deviation, median, 25th percentile, 75th percentile
and range. The SPSS Software Version 10.0 was employed
for all calculations,.
Results
Clinical and histological patient data
Table 1 provides clinical data on the tumor samples, while
Table 2 shows the histological classification of the tissue
specimens.
Expression of telomerase activity (TA) and hTERT mRNA
in primary testicular GCT hTERT transcripts and TA were
detected in 34 / 42 of TGCT as well as in all (n = 7 / 7) IT-
GNU (mean NhTERT = 43.1 ± 24.1 standard deviation,
range 0.00–99, mean TA 0.34 ± 24.1 range 0.00–0.74).
Correlating the histopathology with hTERT mRNA expres-
sion and telomerase activity (TA) revealed significant dif-
ferences between mature teratomas and other germ cell
tumors (Kruskal-Wallis test, p < 0.001) (see Table 2, Fig. 1
and Fig. 2). The Kruskal-Wallis test showed no statistically
significant differences in telomerase activity and hTERT
expression within the group of undifferentiated semino-
matous and nonseminomatous germ cell tumors.
Analysis disclosed little or no telomerase activity or hTERT
gene expression in any of the pure mature teratomas ex-
amined (Kruskal-Wallis test, p < 0.001).
Embryonal carcinomas had the highest hTERT mRNA ex-
pression and TA (mean NhTERT = 75.8 (± 14.5), TA 0.55 (±
0.16)). Embryonal-like somatically differentiated imma-
ture teratomas evidenced a mean hTERT mRNA expres-
sion of NhTERT = 54.3 (± 12.4) (TA 0.39 (± 0.12). TGCTs
showing extraembryonal differentiation such as yolk sac
tumors (mean NhTERT = 37.3 (± 12)) (TA 0.39 (± 0.15)
and choriocarcinomas had a lower mean hTERT mRNA
expression (NhTERT = 37.6 (± 6.7)) and TA (mean TA 0.42
(± 7.9)) than embryonal carcinomas.
Pure seminomas had a mean hTERT copy number of
NhTERT = 41.2 (± 11.6), which was markedly below that of
EC (mean NhTERT = 75.8 (± 14.5)).
The hTERT mRNA expression level in ITGNU (ITGNU
component > 30% of the tubules) was similar to that in
seminomas (mean NhTERT 46.2 (± 21.3)) and decreased as
the percentage of the ITGNU component increased. Thus,
this inverse correlation of the ITGNU component and the
NhTERT copy number could be explained by an increasing
presence of germline cells and subsequent hTERT expres-
sion associated with a decreasing ITGNU component in
testicular tissue specimens.
In contrast, mature teratomas, which are tumors histolog-
ically characterized by well-differentiated tissue compo-
nents of all 3 germ layers [33], showed a nearly complete
downregulation of hTERT gene expression (mean NhTERT
= 3.2 (± 3.1)) and a lack of telomerase activity (mean TA
0.03 ± 0.06). The histopathological diagnosis of 4 terato-
mas as mature types had to be revised because they unex-
pectedly expressed hTERT mRNA and telomerase activity
and the histopathological reexamination did reveal areas
with yolk sac tumor (in two cases), yolk sac tumor / em-
bryonal carcinoma (one case) immature cartilage (one
case).
Table 1: Patient characteristics
Characteristics No.
Patients 80
Median age in y
Control group 30.5
Patients with testicular germ cell tumors
Pure seminoma 32.7
Nonseminoma 25.1
Histology
Benign testicular tissue specimens (control group) 38
Germ cell tumors 42
Intratubular germ cell neoplasia unclassified 7
Clinical stage of patients with primary TGCT*
I2 4
II 11
III 7
ITGCNU (>30%) = intratubular germ cell neoplasia, unclassified in 
more than 30 % of the tubuli. TGCT = Testicular germ cell tumor, 
*Clinical stage according to the UICC classification [43].BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/32
Page 5 of 9
(page number not for citation purposes)
Telomerase activity and hTERT mRNA expression in be-
nign testicular tissue
Telomerase activity and hTERT mRNA expression were
found to correlate with germ cell differentiation. Expres-
sion of hTERT mRNA (NhTERT = 132.0 (± 48.0)) proved to
be highest in tissue samples with normal gametogenesis
but was significantly reduced in those with maturation ar-
rest at the spermatocyte I° and II° level (NhTERT = 53.0 (±
17.3)) and at the level of spermatogonia (NhTERT = 23.2
(± 7.8)), as described previously [34]. In patients with
germ cell aplasia, hTERT mRNA expression was absent in
6 of 8 cases and only minimal in two with marked granu-
locytic infiltration (NhTERT = 7.2 and 4.1), indicating that,
hTERT expression is germ-cell-specific in benign testicular
Table 2: hTERT mRNA expression and hTR in testicular germ cell tumors
Histology No. Telomerase activity Median (25th 
percentile, 75th percentile) (range)
NhTERT * Median (25th percentile, 
75th percentile) (range)
ITGCNU 7 0.50 (0.42, 0.53) (0.39–0.55) 43.1 (29.4, 67.8) (13.0 – 74.0)
Seminoma 13 0.45 (0.31, 0.63) (0.19–0.73) 42.3 (30.9, 50.9) (20.0 – 58.9)
EC 9 0.55 (0.47, 0.63) (0.42–0.74) 73.6 (63.4, 88,7) (56.0 – 99.7)
Yolk sac tumor 4 0.39 (0.34, 0.46) (0.3–0.53) 37.7 (24.8, 49.4) (22.4 – 51.4)
Immature teratoma 6 0.52 (0.34–0.70) 52.6 (42.8, 63.4) (42.5–76.0)
Choriocarcinoma 2 0.42 (0.3, 0.55) 37.6 (32.8 and 42.3)
Mature teratoma 8 0.03 (0.01, 0.05) (0.00 – 0.08) 3.7 (3.1, 4.5) (0 – 6.7)
EC = Embryonal carcinoma; ITGCNU = intratubular germ cell neoplasia, unclassified in more than 30 % of the tubuli. *Normalized hTERT mRNA 
expression
Figure 1
Quantification of hTERT mRNA () in germ cell tumor samples by real-time RT PCR. Quantification of PBGD mRNA (x)
served as a reference for relative quantification. The copy numbers of the starting template were calculated by comparing the
relative fluorescence signals of samples to external hTERT mRNA standards. X axis: cycle number, Y axis: fluorescence emis-
sion; Tissue specimen with NhTERT = 85,2 copies. BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/32
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tissue. (Table 3 gives a summary of hTERT mRNA and te-
lomerase activity expression in benign testicular tissue).
Figure 2
Quantification of hTERT mRNA () in germ cell tumor samples by real-time RT PCR. Quantification of PBGD mRNA (x)
served as a reference for relative quantification. The copy numbers of the starting template were calculated by comparing the
relative fluorescence signals of samples to external hTERT mRNA standards. X axis: cycle number, Y axis: fluorescence emis-
sion; tissue specimen with NhTERT = 2,1 copies. 
Table 3: hTERT mRNA expression in benign testicular tissue specimens
Histology Telomerase activity (median) 25th 
percentile, 75th percentile (range)
hTERT mRNA (median) 25th per-
centile, 75th percentile (range)
Norm n = 12 559.2 127.2
182.1, 521.8 104.2, 140.3
(233 – 884) (80.5 – 246.7)
MA n = 14 474.7 39.0
162.1, 320.4 25.0, 70.4
(227 – 899) (13.1–83.9)
SCOS n = 12 7.2 2.2
3.1, 16 0.0, 5.3
(0 – 32) (0.00 – 7.20)
hTERT = human telomerase reverse transcriptase. MA = maturation arrest (Johnsen score 3–5); Norm = normal gametogenesis; SCOS = Sertoli-
cell-only syndrome.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/32
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Discriminant analysis
The Kruskal-Wallis test showed significant differences be-
tween NhTERT copies expressed by mature teratomas and
other subgroups of nonseminomas and seminomas (p <
0.001).
Discriminant analysis disclosed a 97% (94.5%) accuracy
of NhTERT (telomerase activity) for classification of germ
cell tumors in the group of mature teratomas versus the
other subgroups. The detection technique had a specificity
of 96% (94.2 %) and a sensitivity of 100% (100%) with a
selected cutoff value of NhTERT = 15 (telomerase activity
10 units) for differentiating mature teratomas from the
other subgroups. In the control group, discriminant anal-
ysis showed that detection of hTERT (or TA) had a high
predictive value (86.8%) (predictive value for TA 58%) for
correct classification in one of the three benign histologi-
cal subgroups.
Discussion
This study is the first to report levels of telomerase activity
and hTERT mRNA expression in adult male GCT by using
real-time PCR. We quantified telomerase activity (TA) in
these samples by a semiquantitative PCR ELISA to enable
comparative studies with hTERT levels.
Though TA is thought to play an important role in the de-
velopment of most cancers [5], its detection in testicular
tissue specimens is not specific for malignant disease
[6,19]. TA is also found in benign testicular tissue. There,
it can be attributed to germline cells [35] and is downreg-
ulated during spermatogenesis [19,36,37].
Unlike the majority of malignant tumors, TGCT arise
from primarily telomerase-positive cells [6]. According to
a widely accepted theory postulated by Skakkebaek, all
adult TGCTs except for spermatocytic seminomas are at-
tributable to carcinoma in situ [26]. TGCTs can be subdi-
vided into two main types: seminomas (SE) and
nonseminomas (NSE) [33]. Seminomas retain the mor-
phology of gonocytes. NSE-TGCTs display embryonal and
extraembryonal differentiation patterns, including primi-
tive zygotic (embryonal carcinoma), embryonal-like so-
matic (teratoma), and extraembryonal differentiation
(choriocarcinoma, yolk-sac tumor). Of all tumors with
differentiated elements, differentiated (mature) teratomas
exhibit the most complete differentiation, often contain-
ing cell types such as those composing cartilage and neu-
ral tissue [33].
The NhTERT gene expression and TA quantified in malig-
nant TGCT underlines the above-mentioned prevailing
concepts on the histogenesis of germ cell tumors. While
embryonal carcinomas were found to have the highest
mean hTERT mRNA and TA levels, downregulation of
hTERT mRNA expression and TA was seen with increasing
embryonal-like somatic tumor differentiation.
We attribute the reduced hTERT expression and telomer-
ase activity to:
1) A downregulation of hTERT and telomerase activity in
the course of tumor cell differentiation.
2) Tissue-specific factors of the individual tumors such as
necrotic areas in choriocarcinomas or extensive stromal
components in yolk sac tumors.
Mature teratomas showed virtually no hTERT mRNA ex-
pression or TA (Table 2). Interestingly, the loss of hTERT
gene expression and TA in mature teratomas correlated
with the limited proliferation capacity and chemotherapy
resistance of these tumors, which, unlike all other TGCTs,
are insensitive to chemotherapy [38]. The fact that the his-
topathological control examination revealed areas with
yolk sac tumor (in two cases), yolk sac tumor / embryonal
carcinoma (one case) immature cartilage (one case) in
four teratomas which unexpectedly expressed hTERT and
showed TA after being histologically classified as the ma-
ture type points to the possibility of using hTERT mRNA
and TA detection for molecular-biological validation/con-
firmation of a histopathologically diagnosed mature ter-
atoma.
Among TGCT showing extraembryonal differentiation,
both yolk sac tumors and choriocarcinomas with a clini-
cally poor prognosis [39] had a lower mean NhTERT ex-
pression and TA than embryonal carcinomas and
seminomas. This suggests that the level of hTERT mRNA
expression and TA in TGCT correlates with the differenti-
ation status of the tumors [40].
Benign testicular tissue showed a close correlation be-
tween impaired gametogenesis and downregulation of
hTERT gene expression and TA. Expression was highest in
testicular tissue specimens with normal gametogenesis
and downregulated in those with maturation arrest. It re-
mains unclear whether the downregulation of hTERT gene
expression which we observed is causally associated with
the impairment of germ cell differentiation, as has been
demonstrated for mice genetically deficient in murine tel-
omerase RNA [41,42] or whether there is no correlation.
In conclusion, our data indicate that TA and hTERT mRNA
expression were detectable in all undifferentiated TGCTs.
Mature teratomas were the only germ cell tumors that
showed no hTERT expression or TA. This suggests an in-
verse correlation between the differentiation status and
hTERT mRNA expression in TGCT. Thus, detection of
hTERT mRNA expression and TA in tumors histopatho-BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/32
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logically classified as differentiated teratomas enables a
molecular-diagnostic confirmation of this tumor subtype.
Since the differentiation status of GCTs correlates with
their clinical behavior, as demonstrated for the less differ-
entiated EC, the quantitative detection of hTERT mRNA
copies and TA could provide molecular augmentation of
the histopathological diagnosis. However, prospective
clinical studies are required to substantiate these findings.
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